Evidence Snapshot

Peroxisome proliferator-activated receptor gamma

CHEMBL235 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T04:43:38Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 1:43 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL235

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Peroxisome proliferator-activated receptor gamma as ChEMBL target CHEMBL235, mapped to UniProt P37231. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Peroxisome proliferator-activated receptor gamma

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL235

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P37231

Peroxisome proliferator-activated receptor gamma

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Peroxisome proliferator-activated receptor gamma matters

As of 2026-09-13

Peroxisome proliferator-activated receptor gamma is reviewed as Peroxisome proliferator-activated receptor gamma (UniProt P37231); Peroxisome proliferator-activated receptor gamma shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.; 14 linked drugs keep this evidence frame grounded.; the current evidence base includes 32 approved drugs, 8182 compounds, and 1793 assays, with lead potency reaching pChEMBL 10.7.

Protein context

Peroxisome proliferator-activated receptor gamma

Peroxisome proliferator-activated receptor gamma Sequence length is 505 aa.

Review this target as Peroxisome proliferator-activated receptor gamma, mapped to UniProt P37231. Sequence length is 505 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P37231 Protein

Disease context

type 2 diabetes mellitus

Peroxisome proliferator-activated receptor gamma shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 14 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALEGLITAZAR, ARHALOFENATE, BALAGLITAZONE.

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include ALEGLITAZAR, ARHALOFENATE, BALAGLITAZONE, INT131. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 14 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 32 approved drugs, 8182 compounds, and 1793 assays for this target. The dominant activity type is EC50. CHEMBL1813011 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL1813011 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine

32 approved pChEMBL 10.7

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Peroxisome proliferator-activated receptor gamma matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P37231, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why type 2 diabetes mellitus is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

8182

Total Compounds

1793

Total Assays

Approved Drugs

IC50: 2321.0, KI: 622.0, EC50: 5401.0, KD: 106.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL1813011	10.7	EC50	—
No preferred name CHEMBL3545280	10.4	EC50	Clinical
No preferred name CHEMBL1813008	10.3	EC50	—
No preferred name CHEMBL434063	10.3	Ki	—
No preferred name CHEMBL3678131	10.2	IC50	—

Approved Drugs

Structure	Compound	First Approval
	ELAFIBRANOR CHEMBL3707395	2024
	ROSIGLITAZONE CHEMBL121	1999
	PIOGLITAZONE CHEMBL595	1999
	ROSIGLITAZONE MALEATE CHEMBL843	1999
	TELMISARTAN CHEMBL1017	1998
	TROGLITAZONE CHEMBL408	1997
	FENOFIBRATE CHEMBL672	1993
	GLYBURIDE CHEMBL472	1984
	LEVOTHYROXINE CHEMBL1624	1982
	LIOTHYRONINE CHEMBL1544	1956

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T04:43:38Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 1:43 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL235